A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
Unknown status
European Commission
Phase 3
2005-01-01
Tuberculosis is currently treated with a 6-month course regimen. During this time many
patients might fail to adhere to treatment and default, increasing the risk of recurrent
disease which might be multidrug resistant. A shorter duration of treatment is expected to
provide improved patient compliance and at least equal or better clinical outcome. The aim of
the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four
months duration for the treatment of pulmonary tuberculosis,
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
Unknown status
World Health Organization
Phase 3
2005-01-01
Tuberculosis is currently treated with a 6-month course regimen. During this time many
patients might fail to adhere to treatment and default, increasing the risk of recurrent
disease which might be multidrug resistant. A shorter duration of treatment is expected to
provide improved patient compliance and at least equal or better clinical outcome. The aim of
the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four
months duration for the treatment of pulmonary tuberculosis,
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
Unknown status
Institut de Recherche pour le Developpement
Phase 3
2005-01-01
Tuberculosis is currently treated with a 6-month course regimen. During this time many
patients might fail to adhere to treatment and default, increasing the risk of recurrent
disease which might be multidrug resistant. A shorter duration of treatment is expected to
provide improved patient compliance and at least equal or better clinical outcome. The aim of
the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four
months duration for the treatment of pulmonary tuberculosis,
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
